Development of liposomal anthracyclines: From basics to clinical applications

Journal of Controlled Release

Volumn 53, Issue 1-3, 1998, Pages 275-279

  Gabizon, Alberto ^a   Goren, Dorit ^a   Cohen, Rivka ^a   Barenholz, Yechezkel ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; DRUG CARRIER; LIPOSOME;

BLOOD VESSEL PERMEABILITY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG STABILITY; ENCAPSULATION; PLASMA CLEARANCE; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; DRUG CARRIERS; HUMANS; LIPOSOMES; SARCOMA, KAPOSI; TISSUE DISTRIBUTION;

EID: 0032580445     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(97)00261-7     Document Type: Conference Paper

References (18)

1. D. Lasic, F. Martin, Stealth Liposomes, CRC Press, Boca Raton, FL, 1995.
2. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54:1994;987-992.
3. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta. 1151:1993;201-215.
4. Gabizon A. Liposome circulation time and tumor targeting: Implications for cancer chemotherapy. Adv. Drug Deliv. Rev. 16:1995;285-294.
5. Gabizon A., Goren D., Horowitz A.T., Tzemach D., Lossos A., Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Deliv. Rev. 17:1997;337-344.
6. Amselem S., Gabizon A., Barenholz Y. Optimization and upscaling of doxorubicin containing liposomes for clinical use. J. Pharm. Sci. 79:1990;1045-1052.
7. Gabizon A., Isacson R., Libson E., Kaufman B., Uziely B., Catane R., Gera-BenDor C., Rabello E., Cass Y., Peretz T., Sulkes A., Chisin R., Barenholz Y. Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 7:1994;779-786.
8. Cullis P.R., Bally M.B., Madden T.D., Mayer L.D., Hope M.J. pH gradients and membrane transport in liposomal systems. TIBTECH (Elsevier). 9:1991;268-272.
9. Lasic D.D., Frederik P.M., Stuart M.C.A., Barenholz Y., McIntosh T.J. Gelation of liposome interior: A novel method for drug encapsulation. FEBS Lett. 312:1992;255-258.
10. Working P.K., Dayan A.D. Pharmacological-Toxicological Expert Report: Caelyx (Stealth Liposomal Doxorubicin HCl). Human Exp. Toxicol. 15:1996;752-785.
11. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., Martin F.J. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA. 88:1991;11460-11464.
12. Allen T.M. The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocytic system. Adv. Drug Deliv. Rev. 13:1994;285-309.
13. 1 shortens the blood circulation time of liposomes in rats. Pharm. Res. 12:1995;508-512.
14. Gabizon A., Barenholz Y., Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharm. Res. 10:1993;703-708.
15. Huang S.K., Lee K.-D., Hong K., Friend D.S., Papahadjopoulos D. Microscopic localization of sterically-stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52:1992;5135-5143.
16. Gabizon A.A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52:1992;891-896.
17. Harrison M., Tomlinson D., Stewart S. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma. J Clin. Oncol. 13:1995;914-920.
18. Uziely B., Jeffers S., Isacson R., Kutsch K., Wei-Tsao D., Yehoshua Z., Muggia F.M., Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 13:1995;1777-1785.